Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.

TSX:TH - Post by User

Theratechnologies Inc > ATM

<< Previous

Bullboard Posts

Next >>

Comment by longterm56on Jul 26, 2021 6:52pm

74 Views

Post# 33608278

RE:ATM

Any ideas on what will make the stock price go up 25-40% from July 23 closing price before the Phase 1 results?

-LT

palinc2000 wrote:

What is more likely is a more balanced approach with some drawdowns at prices representing 25-40% increase from the July 23 closing prices ,,,
My own expectations is at least 35-40 million $ before the release of Phase 1 Clinical Results

I will not hide behind the ignore button id I am wrong